|
1.
|
|
|
2.
|
|
51 p, 698.6 KB |
Nuclearity and Grothendieck-Lidskii formula for quaternionic operators
/
Cerejeiras, Paula (Universidade de Aveiro. Departamento de Matemática) ;
Colombo, Fabrizio (Politecnico di Milano. Dipartimento di Matematica) ;
Debernardi Pinos, Alberto (Universitat Autònoma de Barcelona. Departament de Matemàtiques) ;
Kähler, Uwe (Universidade de Aveiro. Departamento de Matemática) ;
Sabadini, Irene (Politecnico di Milano. Dipartimento di Matematica)
We introduce an appropriate notion of trace in the setting of quaternionic linear operators, arising from the well-known companion matrices. We then use this notion to define the quaternionic Fredholm determinant of trace-class operators in Hilbert spaces, and show that an analog of the classical Grothendieck-Lidskii formula, relating the trace of an operator with its eigenvalues, holds. [...]
2024 -  10.1016/j.aim.2024.109558
Advances in mathematics, Vol. 442 (April 2024) , art. 109558
|
|
|
3.
|
|
9 p, 1.6 MB |
Towards a transdisciplinary approach in the training of teachers : Creating procedures in learning and teaching in higher education
/
Saura Mas, Sandra (Centre de Recerca Ecològica i d'Aplicacions Forestals) ;
Blanco-Romero, Asunción (Universitat Autònoma de Barcelona. Departament de Geografia) ;
Barrera, Jaume 1954- ed. (Universitat Autònoma de Barcelona. Departament de Didàctica de l'Expressió Musical, Plàstica i Corporal) ;
Universitat Autònoma de Barcelona.
Departament de Biologia Animal, de Biologia Vegetal i d'Ecologia
For decades we have been immersed in a constant change in our society, registered together with an increase in its degree of complexity. This greatly affects the currently prevailing educational axioms, making them obsolete, which implies, according to our hypothesis, the need for a process of revision and innovation of existing models. [...]
2021 - 10.4995/HEAd21.2021.13037
7th International Conference on Higher Education Advances (HEAd'21), (2021) , p. 773-781
|
|
|
4.
|
|
19 p, 1.5 MB |
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
/
Wieduwilt, M.J. (University of Oklahoma) ;
Metheny, L. (University Hospitals Seidman Cancer Center) ;
Zhang, M.J. (Medical College of Wisconsin) ;
Wang, H.L. (Center for International Blood and Marrow Transplant Research) ;
Estrada-Merly, N. (Center for International Blood and Marrow Transplant Research) ;
Marks, D.I. (University Hospitals Bristol National Health Service Trust) ;
Samer Al-Homsi, A. (New York University Langone Health) ;
Muffly, L. (Stanford University) ;
Chao, N. (Duke University Medical Center) ;
Rizzieri, D. (Duke University) ;
Gale, R.P. (Imperial College London) ;
Gadalla, S.M. (National Institutes of Health) ;
Cairo, M. (New York Medical College) ;
Mussetti, Alberto (Institut d'Investigació Biomèdica de Bellvitge) ;
Gore, S. (Yale New Haven Hospital) ;
Bhatt, V.R. (University of Nebraska Medical Center) ;
Patel, S.S. (University of Utah) ;
Michelis, F.V. (Princess Margaret Cancer Centre) ;
Inamoto, Y. (National Cancer Center Hospital) ;
Badawy, S.M. (Northwestern University Feinberg School of Medicine) ;
Copelan, E. (Atrium Health) ;
Palmisiano, N. (Thomas Jefferson University) ;
Kharfan-Dabaja, M.A. (Mayo Clinic) ;
Lazarus, H.M. (Case Western Reserve University) ;
Ganguly, S. (University of Kansas Health System) ;
Bredeson, C. (The Ottawa Hospital Transplant and Cellular Therapy Program) ;
Perez, M.A.D. (Hospital Infantil Universitario Niño Jesus) ;
Cassaday, R. (University of Washington) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Ballen, K. (Division of Hematology/Oncology. University of Virginia Health System) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Wirk, B. (Penn State Cancer Institute) ;
Bacher, U. (University of Bern) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Bashey, A. (Northside Hospital) ;
Murthy, H.S. (Mayo Clinic) ;
Yared, J.A. (University of Maryland) ;
Aldoss, I. (City of Hope Medical Center) ;
Farhadfar, N. (University of Florida College of Medicine) ;
Liu, H. (University of Chicago Medicine) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Waller, E.K. (Emory University) ;
Solh, M. (Northside Hospital) ;
Seftel, M.D. (University of British Columbia) ;
van der Poel, M. (Maastricht University Medical Center) ;
Grunwald, M.R. (Atrium Health) ;
Liesveld, J.L. (University of Rochester Medical Center) ;
Kamble, R.T. (Baylor College of Medicine) ;
McGuirk, J. (University of Kansas Health System) ;
Munker, R. (University of Kentucky) ;
Cahn, Jean-Yves (Universite Grenoble Alpes) ;
Lee, J.W. (The Catholic University of Korea) ;
Freytes, C.O. (University of Texas Health Science Center) ;
Krem, M.M. (University of Kentucky) ;
Winestone, L.E. (University of California) ;
Gergis, U. (Thomas Jefferson University) ;
Nathan, S. (Rush University Medical Center) ;
Olsson, R.F. (Karolinska Institutet) ;
Verdonck, L.F. (Isala Clinic) ;
Sharma, A. (St. Jude Children's Research Hospital) ;
Ringden, O. (Karolinska Institutet) ;
Friend, B.D. (Baylor College of Medicine) ;
Cerny, J. (University of Massachusetts Medical Center) ;
Choe, H. (The Ohio State University Wexner Medical Center) ;
Chhabra, S. (Center for International Blood and Marrow Transplant Research) ;
Nishihori, T. (Moffitt Cancer Center) ;
Seo, S. (Dokkyo Medical University) ;
George, B. (Christian Medical College) ;
Baxter-Lowe, L.A. (Children's Hospital Los Angeles) ;
Hildebrandt, G.C. (University of Kentucky) ;
de Lima, M. (University Hospitals Case Medical Center) ;
Litzow, M. (Mayo Clinic Rochester) ;
Kebriaei, P. (The University of Texas MD Anderson Cancer Center) ;
Hourigan, C.S. (National Institutes of Health) ;
Abid, M.B. (Medical College of Wisconsin) ;
Weisdorf, D.J. (University of Minnesota) ;
Saber, W. (Center for International Blood and Marrow Transplant Research) ;
Universitat Autònoma de Barcelona
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. [...]
2022 - 10.1182/bloodadvances.2021004916
Blood advances, Vol. 6 Núm. 1 (november 2022) , p. 339-357
|
|
|
5.
|
|
29 p, 401.7 KB |
Epigenetic targets in B- and T-cell lymphomas : latest developments
/
Ribeiro, Marcelo L. (Sao Francisco University Medical School) ;
Sánchez Vinces, Salvador (Sao Francisco University Medical School) ;
Mondragón, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Non-Hodgkin's lymphomas (NHLs) comprise a diverse group of diseases, either of mature B-cell or of T-cell derivation, characterized by heterogeneous molecular features and clinical manifestations. While most of the patients are responsive to standard chemotherapy, immunotherapy, radiation and/or stem cell transplantation, relapsed and/or refractory cases still have a dismal outcome. [...]
2023 - 10.1177/20406207231173485
Therapeutic Advances in Hematology, Vol. 14 (1-12 2023)
|
|
|
6.
|
|
17 p, 1.2 MB |
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia : A Matching Adjusted Indirect Comparison
/
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prawitz, Thibaud (Evidera Inc) ;
Freitag, Andreas (Evidera Inc) ;
Sharma, Anuj (Evidera Inc) ;
Dobi, Balázs (Evidera Inc) ;
Rizzo, Federica (Incyte Biosciences International Sàrl, Morges, Switzerland) ;
Sabatelli, Lorenzo (Incyte Biosciences International Sàrl, Morges, Switzerland) ;
Patos, Petros (Incyte Biosciences International Sàrl, Morges, Switzerland)
Introduction: Efficacy of ponatinib-based treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) has not been compared to imatinib-based treatments in head-to-head clinical trials. [...]
2023 - 10.1007/s12325-023-02497-y
Advances in Therapy, Vol. 40 Núm. 7 (july 2023) , p. 3087-3103
|
|
|
7.
|
|
10 p, 685.7 KB |
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia : the phase 2 CAPTIVATE study
/
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Tam, Constantine S. (Monash University) ;
Grigg, Andrew (Austin Hospital) ;
Scarfò, Lydia (Università Vita Salute San Raffaele) ;
Kipps, Thomas J. (University of California. Moores Cancer Center) ;
Srinivasan, Srimathi (Janssen Research & Development) ;
Mali, Raghuveer Singh (Pharmacyclics LLC. an AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Szafer Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ;
Choi, Michael (University of California)
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). [...]
2023 - 10.1182/bloodadvances.2023010236
Blood advances, Vol. 7 Núm. 18 (26 2023) , p. 5294-5309
|
|
|
8.
|
|
10 p, 345.6 KB |
Momelotinib long-term safety and survival in myelofibrosis : integrated analysis of phase 3 randomized controlled trials
/
Verstovsek, Srdan (The University of Texas, USA) ;
Mesa, Ruben (UT Health San Antonio Cancer Center, San Antonio, USA) ;
Gupta, Vikas (Princess Margaret Cancer Centre, Toronto, Canada) ;
Lavie, David (Hadassah-Hebrew University Medical Center, Jerusalem, Israel) ;
Dubruille, Viviane (Centre Hospitalier Universitaire de Nantes (CHU de Nantes), Nantes, France) ;
Cambier, Nathalie (Centre hospitalier r ' egional universitaire de Lille (CHRU Lille), Lille, France) ;
Platzbecker, Uwe (University of Leipzig, Germany) ;
Hus, Marek (Uniwersytet Medyczny w Lublinie, Lublin, Poland) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Oh, Stephen T. (Washington University School of Medicine, St. Louis, USA) ;
Kiladjian, Jean Jacques (Universite de Paris, France) ;
Vannucchi, Alessandro M. (University of Florence, Careggi University Hospital, Florence, Italy) ;
Gerds, Aaron (Cleveland Clinic, USA) ;
Egyed, Miklos (Teaching Hospital Mor Kaposi, Kaposv ' ar, Hungary) ;
Mayer, Jiří (Masaryk University, Brno, Czech Republic) ;
Sacha, Tomasz (Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland) ;
Kawashima, Jun (Sierra Oncology, San Mateo, CA) ;
Morris, Marc (Sierra Oncology, San Mateo, CA) ;
Huang, Mei (Sierra Oncology, San Mateo, CA) ;
Harrison, Claire (National Health Services (NHS) Foundation Trust, London, United Kingdom)
Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). [...]
2023 - 10.1182/bloodadvances.2022009311
Blood advances, Vol. 7 Núm. 14 (july 2023) , p. 3582-3591
|
|
|
9.
|
|
14 p, 2.7 MB |
GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
/
Zhang, Yu Wei (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mess, Julian (University of Freiburg) ;
Lalioti, Maria Eleni (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Romero-Mulero, Mari Carmen (University of Freiburg, Germany) ;
Obier, Nadine (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Karantzelis, Nikolaos (University Medical Center Freiburg, Germany) ;
Rettkowski, Jasmin (University of Freiburg, Germany) ;
Schönberger, Katharina (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Karabacz, Noemie (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Jäcklein, Karin (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Morishima, Tatsuya (Kumamoto University, Japan) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Romecin, Paola (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martinez, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Takizawa, Hitoshi (Kumamoto University, Japan) ;
Shoumariyeh, Khalid (University of Freiburg, Germany) ;
Renders, Simon (Heidelberg University Hospital (Alemanya)) ;
Zeiser, Robert (University of Freiburg, Germany) ;
Pahl, Heike L. (University Medical Center Freiburg, Germany) ;
Béliveau, François (Quebec leukemia cell bank. Hopital Maisonneuve-Rosemont, Montreal, Canada) ;
Hébert, Josee (Quebec leukemia cell bank. Hopital Maisonneuve-Rosemont, Montreal, Canada) ;
Lehnertz, Bernhard (University of Montreal, Canada) ;
Sauvageau, Guy (University of Montreal, Canada) ;
Menendez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cabezas-Wallscheid, Nina (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany)
Leukemia stem cells (LSCs) share numerous features with healthy hematopoietic stem cells (HSCs). G-protein coupled receptor family C group 5 member C (GPRC5C) is a regulator of HSC dormancy. However, GPRC5C functionality in acute myeloid leukemia (AML) is yet to be determined. [...]
2023 - 10.1182/bloodadvances.2023010460
Blood advances, Vol. 7 Núm. 24 (december 2023) , p. 7525-7538
|
|
|
10.
|
|
15 p, 3.6 MB |
Unraveling the genetics of transformed splenic marginal zone lymphoma
/
Grau, Marta (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
López, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Navarro, Alba (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Frigola, Gerard (Hospital Clínic i Provincial de Barcelona) ;
Nadeu, Ferran (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Clot, Guillem (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bastidas-Mora, Gabriela (Hospital Clínic i Provincial de Barcelona) ;
Alcoceba, Miguel (Hospital Universitario de Salamanca) ;
Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blanes, Margarita (Hospital General Universitario de Elda) ;
Colomer, Dolors (Hospital Clínic i Provincial de Barcelona) ;
Costa, Dolors (Hospital Clínic i Provincial de Barcelona) ;
Domingo-Domenech, Eva (Institut d'Investigació Biomèdica de Bellvitge) ;
Enjuanes, Anna (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Escoda, Lourdes (Hospital Universitari Joan XXIII de Tarragona) ;
Forcada, Pilar (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Giné, Eva (Hospital Clínic i Provincial de Barcelona) ;
Lopez-Guerra, Mónica (Hospital Clínic i Provincial de Barcelona) ;
Ramón, Olga (Hospital General de Igualada) ;
Rivas-Delgado, Alfredo (Hospital Clínic i Provincial de Barcelona) ;
Folch, Laura Vicente (Consorci Sanitari de Terrassa) ;
Wotherspoon, Andrew (Royal Marsden NHS Foundation Trust, United Kingdom) ;
Climent, Fina (Institut d'Investigació Biomèdica de Bellvitge) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
López-Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Matutes, Estella (Hospital Clínic i Provincial de Barcelona) ;
Bea, Sílvia (Hospital Clínic i Provincial de Barcelona)
The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. [...]
2023 - 10.1182/bloodadvances.2022009415
Blood advances, Vol. 7 Núm. 14 (july 2023) , p. 3695-3709
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
